Welcome to our dedicated page for Casi Pharmaceuticals news (Ticker: CASIF), a resource for investors and traders seeking the latest updates and insights on Casi Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Casi Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Casi Pharmaceuticals's position in the market.
CASI Pharmaceuticals (OTCQB: CASIF) reported first half 2026 results and clinical, corporate, and listing developments. Revenue was $9.8 million, down 5.8% year over year, while gross profit rose to $7.7 million. Net loss narrowed to $20.0 million from $24.1 million. Operating expenses decreased in research and development and selling and marketing but increased in general and administrative, partly from higher legal fees. CASI completed a $15 million related-party convertible note financing, received a favorable arbitration award exceeding RMB 100 million in the Juventas dispute, and restored the EVOMELA license via settlement with Acrotech. The company advanced CID-103 with first patient dosed in an AMR Phase 1/2 trial in China and completion of Part A enrollment in an ITP Phase 1/2 study. CASI was delisted from Nasdaq in February 2026; its shares began OTCQB quotation as CASIF in April.